X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FDC LTD. NATCO PHARMA/
FDC LTD.
 
P/E (TTM) x 23.1 28.8 80.4% View Chart
P/BV x 17.5 6.0 292.1% View Chart
Dividend Yield % 0.7 0.8 82.8%  

Financials

 NATCO PHARMA   FDC LTD.
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
FDC LTD.
Mar-14
NATCO PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs877144 611.1%   
Low Rs42479 536.1%   
Sales per share (Unadj.) Rs223.447.6 469.7%  
Earnings per share (Unadj.) Rs31.17.6 408.3%  
Cash flow per share (Unadj.) Rs40.39.0 447.0%  
Dividends per share (Unadj.) Rs5.002.25 222.2%  
Dividend yield (eoy) %0.82.0 38.0%  
Book value per share (Unadj.) Rs219.547.5 461.8%  
Shares outstanding (eoy) m33.07177.83 18.6%   
Bonus/Rights/Conversions PABB-  
Price / Sales ratio x2.92.3 124.4%   
Avg P/E ratio x20.914.6 143.2%  
P/CF ratio (eoy) x16.112.3 130.8%  
Price / Book Value ratio x3.02.3 126.6%  
Dividend payout %16.129.6 54.4%   
Avg Mkt Cap Rs m21,50419,784 108.7%   
No. of employees `000NANA-   
Total wages/salary Rs m1,1281,221 92.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,3898,459 87.4%  
Other income Rs m167394 42.5%   
Total revenues Rs m7,5568,852 85.4%   
Gross profit Rs m1,7932,070 86.6%  
Depreciation Rs m304249 122.2%   
Interest Rs m36631 1,180.9%   
Profit before tax Rs m1,2902,184 59.1%   
Minority Interest Rs m460-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309606 51.0%   
Profit after tax Rs m1,0271,353 75.9%  
Gross profit margin %24.324.5 99.2%  
Effective tax rate %23.927.7 86.3%   
Net profit margin %13.916.0 86.9%  
BALANCE SHEET DATA
Current assets Rs m3,6814,355 84.5%   
Current liabilities Rs m3,1231,792 174.3%   
Net working cap to sales %7.630.3 24.9%  
Current ratio x1.22.4 48.5%  
Inventory Days Days8944 201.3%  
Debtors Days Days5925 237.9%  
Net fixed assets Rs m7,6853,025 254.1%   
Share capital Rs m331179 185.2%   
"Free" reserves Rs m6,6708,243 80.9%   
Net worth Rs m7,2598,453 85.9%   
Long term debt Rs m95511 8,924.3%   
Total assets Rs m11,95710,557 113.3%  
Interest coverage x4.571.4 6.3%   
Debt to equity ratio x0.10 10,392.5%  
Sales to assets ratio x0.60.8 77.1%   
Return on assets %11.713.1 88.9%  
Return on equity %14.216.0 88.4%  
Return on capital %20.723.5 88.2%  
Exports to sales %39.413.3 295.7%   
Imports to sales %5.73.3 170.5%   
Exports (fob) Rs m2,9081,126 258.3%   
Imports (cif) Rs m421283 148.9%   
Fx inflow Rs m3,4451,146 300.6%   
Fx outflow Rs m703355 197.8%   
Net fx Rs m2,743791 346.8%   
CASH FLOW
From Operations Rs m1,4401,485 97.0%  
From Investments Rs m-1,089-620 175.8%  
From Financial Activity Rs m-353-753 46.9%  
Net Cashflow Rs m-1113 -1.3%  

Share Holding

Indian Promoters % 52.0 68.9 75.5%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.7 166.8%  
FIIs % 16.6 7.5 221.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 19.0 136.8%  
Shareholders   25,395 23,730 107.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 22, 2018 03:37 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS